Abstract Alpha‐fetoprotein (AFP)‐negative hepatocellular carcinoma (ANHCC) patients
account for more than 30% of the whole entity of HCC patients and are easily misdiagnosed …

Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are two main
types of primary liver cancer, and reliable discrimination is important for optimal treatment …

Early diagnosis of hepatic cancer is a major public health challenge. While changes in
serum N-glycans have been observed as patients progress from liver fibrosis/cirrhosis to …

The early diagnosis of hepatocellular carcinoma (HCC) is of great clinical desirable due to
lack of specific and sensitive markers. Alterations in the sugar chains of glycoprotein …

Defining clinically relevant biomarkers for early stage hepatocellular carcinoma (HCC) in a
high-risk population of cirrhotic patients has potentially far-reaching implications for disease …

Purpose: Hepatocellular carcinoma (HCC) represents an increasing health problem in the
United States. Serum α-fetoprotein, the currently used clinical marker, is elevated in only∼ …

Detection of early-stage hepatocellular carcinoma (HCC) is beneficial for prolonging patient
survival. However, the serum markers currently used show limited ability to identify early …

Hepatocellular carcinoma (HCC) is one of the most common human malignancies.
Therefore, developing the early, high-sensitivity diagnostic biomarkers to prevent HCC is …

Nonalcoholic steatohepatitis (NASH) is rising in prevalence in the United States and is a
growing cause of hepatocellular carcinomas (HCCs). Site-specific glycan heterogeneity on …

Intrahepatic cholangiocellular carcinoma (ICC) is a challenging malignancy marked by
subtle early symptoms and a high mortality rate, making effective diagnostic markers crucial …